Abstract
Abnormalities of DNA methylation play a significant role in initiation and progression of tumors. The aim of the study was the evaluation of the quantitative determination of hypermethylation of DKK4 gene first exon as a biomarker of the breast epithelial cells malignant transformation in patients with adenocarcinoma (2-3 stage). The analysis of DNA methylation was performed by quantitative pyrosequencing using the set PSQ96MA (Qiagen, USA). It was established that DKK4 methylated DNA content in breast adenocarcinoma tissue samples significantly exceeds the same indexes in the unchanged breast tissue taken from the same patients. The average methylated DNA level in conditions of breast cancer equals to 36,8±12,63 percents whereas the same normal breast indexes equal to 19,37±7,1 percents, р≤0,01. The increased content of methylated DNA in DKK4 gene first exon was revealed in 20 samples of breast adenocarcinoma tissues out of 23 (86.96%, P ≤ 0,01); in the rest 3 samples the investigated content of methylated DNA was comparable with the same index in the normal breast tissues.
Highlights
Ɉɰɿɧɤɚ ɪɨɥɿ ɦɟɬɢɥɸɜɚɧɧɹ ɜ «ɦɨɜɱɚɧɧɿ» ɝɟɧɿɜ ɿ ɝɟɧɨɦɧɨʀ ɧɟɫɬɚɛɿɥɶɧɨɫɬɿ ɭɜɚɠɧɨ ɜɢɜɱɚɽɬɶɫɹ ɩɪɨɬɹɝɨɦ ɨɫɬɚɧɧɿɯ ɪɨɤɿɜ [1, 5]
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer / H
Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer / M
Summary
Ɉɰɿɧɤɚ ɪɨɥɿ ɦɟɬɢɥɸɜɚɧɧɹ ɜ «ɦɨɜɱɚɧɧɿ» ɝɟɧɿɜ ɿ ɝɟɧɨɦɧɨʀ ɧɟɫɬɚɛɿɥɶɧɨɫɬɿ ɭɜɚɠɧɨ ɜɢɜɱɚɽɬɶɫɹ ɩɪɨɬɹɝɨɦ ɨɫɬɚɧɧɿɯ ɪɨɤɿɜ [1, 5]. Ⱦɥɹ ɨɰɿɧɤɢ ɦɨɠɥɢɜɨɫɬɿ ɜɢɤɨɪɢɫɬɚɧɧɹ ɦɟɬɢɥɸɜɚɧɧɹ ɩɪɨɦɨɬɨɪɭ ɝɟɧɚ DKK4 ɹɤ ɞɿɚɝɧɨɫɬɢɱɧɨɝɨ ɦɚɪɤɟɪɚ ɛɭɥɨ ɩɪɨɜɟɞɟɧɨ ɜɢɜɱɟɧɧɹ ɜɦɿɫɬɭ ɦɟɬɢɥɨɜɚɧɨʀ ȾɇɄ ɰɶɨɝɨ ɝɟɧɚ ɜ ɡɪɚɡɤɚɯ ɬɤɚɧɢɧɢ ɚɞɟɧɨɤɚɪɰɢɧɨɦɢ ɣ ɭɦɨɜɧɨ ɧɨɪɦɚɥɶɧɨʀ ɬɤɚɧɢɧɢ ɦɨɥɨɱɧɨʀ ɡɚɥɨɡɢ, ɳɨ ɛɭɥɨ ɜɡɹɬɨ ɜɿɞ ɰɢɯ ɠɟ ɯɜɨɪɢɯ. Ɇɚ ɪɢɫɭɧɤɚɯ, ɳɨ ɩɪɟɞɫɬɚɜɥɟɧɿ, ɩɨɤɚɡɚɧɨ ɜɦɿɫɬ ɦɟɬɢɥɨɜɚɧɨʀ ȾɇɄ ɞɥɹ ɤɨɠɧɨɝɨ ɋG ɫɚɣɬɭ ɝɟɧɚ DKK4 ɭ ɡɪɚɡɤɭ ɬɤɚɧɢɧɢ ɚɞɟɧɨɤɚɪɰɢɧɨɦɢ ɦɨɥɨɱɧɨʀ ɡɚɥɨɡɢ ɿ ɜ ɭɦɨɜɧɨ ɧɨɪɦɚɥɶɧɨʀ ɬɤɚɧɢɧɢ.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
